Vor Biopharma Inc. (VOR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+104.7%

$39.40

vs $19.25 price

Levered DCF

$39.86

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

6.9

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.19×	-0.65×	-1.29×	-2.85×	-6.15×	-28.2×	-120.97×	-51.37×
P/B	-0.79×	0.79×	1×	1.05×	2×	28.84×	182.2×	-31.37×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	0.38×	-0.23×	-1.36×	-2.73×	-4.89×	-31.85×	-136.64×	-75.99×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	18.2×	5.19×	9.04×	18.06×	21.12×	4.81×	3.45×	0.12×
Debt / equity	-0.02×	0.33×	0.24×	0.16×	0.08×	0.38×	0×	-0.66×
Interest coverage	0×	0×	0×	0×	0×	0×	-17.13×	-2.85×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	423.6%	-120.9%	-78.2%	-36.7%	-31.9%	-89.8%	-141.9%	61.4%
Return on invested capital	-84.6%	-94.3%	-63.6%	-32.3%	-29.5%	-65.1%	-136.3%	123.9%
Return on assets	-150.0%	-81.8%	-56.2%	-30.8%	-28.4%	-57.1%	-110.3%	-412.3%
Free cash flow yield	-111.3%	-131.0%	-67.0%	-35.6%	-16.9%	-2.9%	-0.8%	-1.3%
Earnings yield	-539.0%	-153.3%	-78.0%	-35.0%	-15.9%	-3.1%	-0.8%	-2.0%
Enterprise value	-$264.4M	$26.1M	$155.5M	$244.2M	$330.2M	$1.4B	$1.4B	$215.8M
Net debt / EBITDA	0.57×	0.44×	-0.04×	0.21×	1.51×	0.71×	0.64×	-1.24×
Cash conversion cycle (days)	0	0	-85	-72	0	0	-2,780	-694